OrbitonOpen research workspace →
Novo Nordisk A/S logo

Novo Nordisk A/S

TSX:NOVOLive AI agent

Novo Nordisk is a global healthcare company with a focus on diabetes care, obesity treatment, and hormone replacement therapy.

Investor website: https://novonordisk.com/

About

Novo Nordisk is a global healthcare company with a focus on diabetes care, obesity treatment, and hormone replacement therapy. The company partners with AWS to accelerate drug discovery through AI and is committed to patient safety and combating falsified medicines.

Verified company data

Shares outstanding
4453.9
Fully diluted shares
4463.0
Projects
["Phase 1\n\nGlucose sensitive insulin\n\nDiabetes\n\nVentus NLRP3i\n\nDiabetes\n\nsiRNA GalXC-GYS2\n\nDiabetes\n\nCNP\n\nDiabetes\n\nNNC16790001\n\nDiabetes\n\nAmylin 355\n\nObesity\n\nAmylin 1213\n\nObesity\n\nSLC25A5\n\nObesity\n\nNext-gen GLP-1\n\nObesity\n\nACSL5i\n\nObesity\n\nInno8\n\nRare Blood Disorders\n\nPhase 2\n\nSubcutaneous Zenagamtide\n\nDiabetes\n\nMonlunabant in DKD\n\nDiabetes\n\nOral Zenagamtide\n\nDiabetes\n\nCDR132L\n\nDiabetes\n\nTriple\n\nDiabetes\n\nOral Zenagamtide\n\nObesity\n\nUBT251 (GGG tri-agonist)\n\nObesity\n\nTriple\n\nObesity\n\nMonlunabant\n\nObesity\n\nNDec\n\nRare Blood Disorders\n\nZaltenibart\n\nRare Blood Disorders\n\nEtavopivat\n\nRare Blood Disorders\n\nPhase 3\n\nCagriSema in T2D\n\nDiabetes\n\nZiltivekimab ASCVD\n\nDiabetes\n\nCoramitug\n\nDiabetes\n\nZiltivekimabin HFpEF\n\nDiabetes\n\nZiltivekimab AMI\n\nDiabetes\n\nSubcutaneous Zenagamtide\n\nObesity\n\nCagrilintide\n\nObesity\n\nEfruxifermin in MASH\n\nObesity\n\nEtavopivat (Sickle Cell Disease)\n\nRare Blood Disorders\n\nFiled\n\nIcosema\n\nDiabetes\n\nInsulin icodec\n\nDiabetes\n\nCagriSema\n\nObesity\n\nSemaglutide 7.2 mg\n\nObesity\n\nDenecimig\n\nRare Blood Disorders"]
Leadership
Maziar Mike Doustdar (President and Chief Executive Officer (CEO), Joined Novo Nordisk in 1992, held various positions in finance, IT, logistics, operations, and marketing, became CEO in August 2025.), Karsten Munk Knudsen (Executive Vice President, Chief Financial Officer (CFO), Member of the board of directors of Hempel A/S and 3Shape Holding A/S, Chair of NNE board of directors.), Thilde Hummel Bøgebjerg (Executive Vice President, Enterprise IT and Quality), Ludovic Helfgott (Executive Vice President, Product & Portfolio Strategy, President of the Novo Nordisk Haemophilia & Haemaglobinopathies Foundation Council.), Martin Holst Lange (Executive Vice President, Research & Development and Chief Scientific Officer (CSO), Member of the board of directors of Pharmacosmos A/S.), Emil Kongshøj Larsen (Executive Vice President, International Operations, Member of the board of the European Federation of Pharmaceutical Industries and Associations (EFPIA).), Kasper Bødker Mejlvang (Executive Vice President, Chemistry, Manufacturing & Control (CMC) & Product Supply), David Moore (Executive Vice President, US Operations, Member of the board of directors of Novasenta Inc.), Tania Sabroe (Executive Vice President, People, Organisation & Corporate Affairs, Member of the Danish Life Science Council.), Elin Jäger (Senior Vice President, Chief of Staff to CEO; Corporate Strategy & Sustainability, Vice chair of the World Diabetes Foundation.), John F. Kuckelman (Senior Vice President, Group General Counsel, Global Legal, IP and Security)

Verified data last updated:

Recent filings